Sintilimab Combined With Bevacizumab Biosimilar for Potentially Resectable Intermediate HCC

Summary

This is a Phase Ib study to evaluate the safety and efficacy of sintilimab combined with bevacizumab biosimilar in patients with potentially resectable intermediate hepatocellular carcinoma (HCC).

Timeline

Start

2021-05-01

Primary completion

2022-05-01

Completion

2023-05-01

Publications

• Sun HC, Zhu XD, Wang ZY, Gao Q, Ji Y, Shi YH, Wang XY, Qiu SJ, Huang C, Shen YH, Zhou J, Fan J. Sintilimab plus bevacizumab followed by resection in intermediate-stage hepatocellular carcinoma: a phase Ib clinical trial with biomarker analysis. BMJ Oncol. 2024 Dec 16;3(1):e000578. doi: 10.1136/bmjonc-2024-000578. eCollection 2024.

Drugs

Indications